Sacituzumab tirumotecan
2870-019
Phase 3 mab active
Quick answer
Sacituzumab tirumotecan for Non Small Cell Lung Cancer is a Phase 3 program (mab) at Merck KGaA, Darmstadt, Germany with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck KGaA, Darmstadt, Germany
- Indication
- Non Small Cell Lung Cancer
- Phase
- Phase 3
- Modality
- mab
- Status
- active